HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Stock Has Average Target Price of $14.87 According to Analysts

Key Points

• Analysts have a “Moderate Buy” consensus on HUTCHMED, with an average one-year price target of $14.87 based on coverage from six analysts.
• Recent ratings were mixed: HSBC, Daiwa and Wall Street Zen upgraded the stock to “buy,” while Goldman Sachs cut its price target from $16 to $14 and maintained a “neutral” rating.
• HUTCHMED shares opened at $15.16 and were reported up 6.8%; institutional investors own 8.82% of the stock, with several funds recently adding to their positions.

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $14.87.

Several analysts recently weighed in on the stock. Weiss Ratings upgraded shares of HUTCHMED from a "sell (d)" rating to a "sell (d+)" rating in a report on Tuesday, October 20th. HSBC raised shares of HUTCHMED from a "hold" rating to a "buy" rating in a research note on Tuesday, September 8th. The Goldman Sachs Group dropped their price objective on shares of HUTCHMED from $16.00 to $14.00 and set a "neutral" rating for the company in a research note on Thursday, July 23rd. Daiwa Securities Group upgraded HUTCHMED from a "hold" rating to a "buy" rating in a report on Thursday, September 3rd. Finally, Wall Street Zen raised HUTCHMED from a "hold" rating to a "buy" rating in a research note on Saturday, August 8th.

HUTCHMED Trading Up 6.8%

Shares of NASDAQ:HCM opened at $15.16 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.50 and a current ratio of 5.64. The firm has a fifty day moving average price of $13.80 and a 200 day moving average price of $13.21. HUTCHMED has a fifty-two week low of $9.77 and a fifty-two week high of $16.33.

Institutional Investors Weigh In On HUTCHMED

Hedge funds have recently made changes to their positions in the stock. Amundi increased its holdings in shares of HUTCHMED by 4.0% during the 1st quarter. Amundi now owns 232,246 shares of the company's stock worth $3,474,000 after buying an additional 8,916 shares during the last quarter. Crossmark Global Holdings Inc. lifted its stake in HUTCHMED by 25.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 106,185 shares of the company's stock worth $1,553,000 after acquiring an additional 21,270 shares in the last quarter. XY Capital Ltd grew its position in HUTCHMED by 115.2% in the 2nd quarter. XY Capital Ltd now owns 104,130 shares of the company's stock worth $1,120,000 after purchasing an additional 55,736 shares during the last quarter. Finally, Janney Montgomery Scott LLC bought a new stake in shares of HUTCHMED during the first quarter worth $365,000. 8.82% of the stock is currently owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED NASDAQ: HCM is a biopharmaceutical company focused on discovering, developing and commercializing medicines for cancer and other serious diseases. The company combines research and development capabilities in China with international development and commercial operations, serving patients and healthcare providers in China, the United States, Europe and other global markets.

HUTCHMED's oncology portfolio includes fruquintinib, a targeted therapy for certain patients with metastatic colorectal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.